New data for Arexvy, GSK's respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
· Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD
· Two doses of vaccine in immunocompromised adults aged 18 and above elicited immune responses similar to one dose in healthy adults aged 50+ and with an acceptable safety profile
· In the US alone, adults aged 18-49 with at least one risk factor for RSV disease could exceed 21 million |
I'm invested so I think it can turn around. There is some promise and focus in the pipeline. If they did anything suicidal like increase the dividend I would be out immediately.
Different sector, but SSE has significantly improved its performance since it rebased its dividend, twice. Not only that but my tax bill on reinvesting has also halved. Dividend reinvestment is an absolutely insane concept really, just keep the money inside the company, job done. Spit out 1 or 2% so investors can cover costs, no more. |
So do we take the view that GSK will continue to underperform and go elsewhere, or believe that the worm will turn here eventually? Whilst it's very frustrating being in this I'm still sticking with the latter. |
GSK has fallen dramatically in the global table in recent years; GW+SKB may have accelerated this decline. |
It is the comparison with AZN which is stark. It pays out much less, always has, but is a 2-bagger over 10 years, without reinvesting dividends. Pharma investors need to understand that as a business it is no different to a mining, company, oil company, for that matter any trading company; there is no infinite pipeline of revenue, assets have to be renewed all the time. |
I prefer to focus on the consequences rather than historic treatments which do not always recognise business trends. |
Well if you really want to know, accounting standards IAS38 (International) and SSAP13 (UK) deal with the accounting treatment of R&D. |
A complex subject. Pharma A carries out R&D and reports a cost. Pharma B buys in third party R&D and puts it on its Balance Sheet and is free to pay whatever dividends. Which is GSK? |
Paying excess dividends is what put GSK into its no growth situation...
I'd say rather that having no growth is what put GSK into its no growth situation, not excess divis. |
Strong bounces around 1450. Interesting watch. |
Paying excess dividends is what put GSK into its no growth situation. It should absolutely not increase payouts until it has a good growth pipeline. |
Q3 announcement next week (Wed 30th) .... ;0) |
I have a reasonable holding here. Holding firm and wanting to add if we get to 1400 (or even 1300) Just sitting on my hands at the moment. The markets are nervy. |
Yes the wider markets are dreadful at the moment |
Yes, patience required ahead of the return to 1800p. It was thought that once the litigation was over (especially when the settlements were announced and the price jumped 84p) that this would take place sooner rather than a return to the doldrums of 1400's. |
Still waiting patiently. |
cumnor, Agree totally. Good post. GSK yield currently 4.1% at share price of 1462p |
Market simply demanding better return for shareholders-3.7% wont cut the ice anymore, whatever GSK's prospects. Needs to be 5% to even consider a look in. No more BS from Emma. Given recent history this is no more low risk than the likes of AV, PHNX or even BARC which are starting to look again at shareholder returns. If GSK wants a premium rating then it needs to pay for it. |
At least Emma can't hide behind zantac anymore |
Been a while but back in to see where it goes from here. |
IN @ 1468.825 ..... ;0) |
Well you did warn everyone I suppose :) |
I actually used the dive in recent price to bed and ISA most of mine so every cloud.. |
Added final trance using dividends today |
Not GSK-specific, whole market a sea of red today. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
